IP Library Granted Patent US 7,270,802
Granted Patent B2
US 7,270,802 · App. 10/036,546 · Granted Sep 18, 2007

Non-lethal temporary incapacitation formulation and novel solvent system

Assignee: Zarc International, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,270,802
App. No.
10/036,546
Granted
Sep 18, 2007
Kind
B2
Abstract

A non-lethal temporarily incapacitating formulation having a new solvent system that has reduced blow back longer hang time when used as an aerosol spray. The solvent and formulation are non-toxic, non-hazardous, non-flammable, highly stable, environmentally safe and able to withstand extreme operating temperatures. The solvent system is a mixture of propylene glycerol dicaprylate/caprate and glycerol tris (2-ethylhexanoate) and is suitable for use for a wide range of automotive, household and industrial applications.

Claims (27)

1. A method for incapacitating a subject, comprising:

providing a non-lethal temporarily incapacitating formulation suitable for use in an aerosol or spray application, the incapacitating formulation comprising

a solvent system comprising a mixture of propylene glycol esters of short chain fatty acids and glycerol tris (2-ethylhexanoate); and

an incapacitating agent; and

applying the non-lethal temporarily incapacitating formulation into the facial area of the subject.

2. The method of claim 1 wherein said applying comprises spraying the non-lethal temporarily incapacitating formulation into the eyes of the subject.

3. The method of claim 1 , wherein the non-lethal temporarily incapacitating formulation further comprises a propellant.

4. The method of claim 3 wherein said propellant is miscible in said solvent system.

5. The method of claim 4 wherein said propellant is carbon dioxide.

6. The method of claims 1 wherein the propylene glycol esters of short chain fatty acids is propylene glycol dicaprylate/caprate.

7. The method of claim 6 wherein the propylene glycol dicaprylate/caprate is present in an amount of 20 to about 80% by weight of the solvent system.

8. The method of claim 6 wherein the propylene glycol dicaprylate/caprate is present in an amount of 45 to about 55% by weight of the solvent system.

9. The method of claim 1 wherein the glycerol tris (2-ethylhexanoate) is present in an amount of 20 to about 80% by weight of the solvent system.

10. The method of claim 6 wherein the solvent system comprises approximately equal amounts of the propylene glycol dicaprylate/caprate and glycerol tris (2-ethylhexanoate).

11. The method of claim 1 , wherein the incapacitating agent is an inflammatory agent.

12. The method of claim 11 wherein the incapacitating agent is selected from the group consisting of synthetic capsaicin, natural capsaicin, dibenzoxazepine (CR), chloroacetophenone (CN), ortho-chlorobenzalmalononitrile (CS), oleoresin capscium (OC), oleoresin paprika, paprika, capsicums (chili peppers), trans-8-methyl-N-vanillyl-6-nonenamide (capsaicin), 8-methyl-N-vanillyl-nonamide (dihydrocapsaicin), 7-methyl-N-vanillyl-octamide (nordihydrocapsaicin), 9-methyl-N-vanillyl-decamide (homodihydrocapsaicin), trams-9methyl-N-vanillyl-7-decenamide (homocapsaicin), (3R, 3p, 5pR)-3,3′-dihydroxy-a′, k-caroten-6′-one (capsanthin), N-vanillyl-octamide, N-vanillyl-nonamide, N-vanillyl-decanamide, N-vanillyl-undecanamide, N-vanillyl-paaiperic acid amide, and mixtures thereof.

13. The method of claim 1 wherein the incapacitating agent is present in an amount of about 0.18% to about 3% by weight of the solvent system.

14. The method of claim 13 wherein the incapacitating agent is present in an amount of about 1.4% to about 1.5% by weight of the solvent system.

15. The method of claim 1 wherein said incapacitating agent comprises an inflammatory agent, and wherein the non-lethal temporarily incapacitating formulation is formulated to cause, upon application of the system to the facial area of a recipient, inflammation to the facial area of the recipient.

16. The method of claim 1 , wherein said applying of the non-lethal temporarily incapacitating formulation into the facial area of the subject causes the subject to experience a symptom selected from the group consisting of immediate closing of the eyes, shortness of breadth, and burning sensation.

17. The method of claim 16 , wherein the symptom lasted no longer than one hour.

18. The method of claim 1 , wherein said applying of the non-lethal temporarily incapacitating formulation into the facial area of the subject causes the subject to experience symptoms comprising immediate closing of the eyes, shortness of breadth, and burning sensation.

19. The method of claim 18 , wherein the symptoms lasted no longer than one hour.

20. The method of claim 1 , wherein said applying comprises defending oneself by applying the non-lethal temporarily incapacitating formulation into the facial area of the subject.

21. The method of claim 1 , wherein said applying comprising applying the non-lethal temporarily incapacitating formulation into the facial area of a person engaged in a bar fight, a domestic disturbance, a hostage situation, a terrorist situation, a barricade situation, or a riot, or a suspect engaged in flight.

22. The method of claim 1 , wherein said applying comprises a law enforcement official applying the non-lethal temporarily incapacitating formulation into the facial area of the subject.

23. The method of claim 1 wherein the incapacitating agent is present in an amount of 0.9% or greater by weight of the solvent system.

Assignments (3)
SECURITY INTEREST Recorded Nov 18, 2005
From: ZARC INTERNATIONAL, INC.
To: NEWTEK SMALL BUSINESS FINANCE, INC.
Reel/Frame 017045/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2005
From: ZARC INTERNATIONAL, INC. A MARYLAND CORPORATION
To: ZARC INTERNATIONAL, INC.
Reel/Frame 017045/0012 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2002
From: LOGHMAN-ADHAM, KAMRAN
To: ZARC INTERNATIONAL, INC.
Reel/Frame 012757/0389 →
Continuity (1)
Related Publication 20030129138A1 · Jul 10, 2003